Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Vaccines Politics

Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine

  • News

Executive Summary

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio roundup of major events in the international biopharma industry over the past week, as reported by Scrip's global team.

Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine

Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.

'I Was Disappointed,' Pfizer CEO Bourla Says Of US Presidential Debate

Pfizer CEO Albert Bourla said he is disappointed in the US politicization of a COVID-19 vaccine in a letter to employees. "We are moving at the speed of science," he said.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 Vaccines Politics
Latest Headlines

Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza

Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse

Stock Watch: The Transatlantic Asymmetries Of Generic Drugs

COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says

See All
UsernamePublicRestriction

Register

SC143053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By